This Presolicitation opportunity from Department Of Health And Human Services was posted on August 27, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

CUSTOM INDUCIBLE KNOCKIN MOUSE

Closed

PCA-NIDDK-02527 Federal

Submission Closed09/01/2026, 09:00:00 AM EDT

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 541714

New

Federal

Illumina NovaSeq 6000 S4 Reagent Kits

Solicitation # 1301434156

Naval Medical Research Center

POSTED

DEADLINE

Presolicitation Notice to Sole Source for Experimental Pathology Laboratories, Inc. (EPL)

Solicitation # Presolicitation_NOI_Sole_Source_EPL

The U.S. Environmental Protection Agency, through the Office of the Chief Procurement Officer's Water, Tribal, and Science Division, intends to award a firm-fixed price purchase order for histology and pathology services of maternal and neonatal rodent specimen organs. The work will be performed at the EPA Headquarters in Washington, DC, and focuses on the toxicologic pathology of environmental contaminants, including PFAS, phthalates, air pollutants, and endocrine-disrupting compounds. This acquisition is intended to continue existing larger studies to maintain data integrity and avoid protocol deviations. The EPA intends to sole source this requirement to Experimental Pathology Laboratories, Inc. (EPL) due to their specialized experience with environmental contaminants, compliance with Good Laboratory Practice regulations, and their ability to accept hand-delivered samples as a local vendor. The procurement falls under NAICS code 541714 for Research and Development in Biotechnology and PSC code AZ11. While the agency intends to award to EPL, other responsible sources may submit capability statements, proposals, or quotations by November 30, 2026. The estimated award date is December 3, 2026. All vendors must maintain a public profile in the System for Award Management and utilize the FedConnect portal for contract communications.

Tribal & Science Division Water

POSTED

DEADLINE

Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS)

Solicitation # ARPA-H-SOL-26-164

The Advanced Research Projects Agency for Health (ARPA-H) is soliciting proposals for the Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS) program under solicitation ARPA-H-SOL-26-164. This five-year initiative aims to create a reusable blueprint for future adaptive seamless platform trials through the integration of three technical areas: a Phaseless Design Engine, Continuous Inference, and Agentic Operations. The program is divided into two stages, with Stage I focusing on capability buildout, FDA engagement, and the onboarding of at least three intervention arms over 24 months, followed by a 36-month Stage II dedicated to validation and deployment. A critical go/no-go milestone is obtaining FDA authorization for the platform Master Protocol IND and at least one investigational arm by the end of Stage I. The government intends to make multiple awards via Other Transaction Agreements to proposers offering the most advantageous solutions based on innovation, feasibility, and technical merit at reasonable prices. Eligible entities must possess a Unique Entity Identifier and active SAM registration. Proposals are submitted in a phased approach, beginning with a Solution Summary and potentially progressing to a Solution Pitch package. Performance will be measured by the successful integration of the three technical areas and the achievement of specific program metrics. All work must adhere to ICH E6(R3) Good Clinical Practice and strict regulatory standards to ensure inspection readiness and participant safety.

Advanced Research Projects Agency For Health (arpa-H)

POSTED

DEADLINE

Solicitation # DARPA-SN-27-18

The Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office is hosting a virtual Industry Day on December 9, 2026, for the Laguna program under Special Notice DARPA-SN-27-18. The program's primary objective is to develop and demonstrate integrated manufacturing approaches that convert abundant domestic feedstocks, such as sugars, ethylene, and BTX, into application-ready specialty chemical formulations. By minimizing intermediate processing steps and separations, the initiative seeks to reduce reliance on vulnerable foreign supply chains. The anticipated 36-month effort is divided into two technical areas: Make and Formulate, which focuses on developing defense-relevant specialty products from U.S. raw materials, and Model, which aims to create predictive tools to optimize the relationship between feedstocks, synthesis, and final product performance. This notice is issued for information and program planning purposes and does not constitute a formal solicitation for proposals. Interested parties must register for the Industry Day event by December 2, 2026. The program requires that resulting products meet or exceed the performance of current military materials, with deliverables including technoeconomic analyses, life cycle assessments, and commercialization strategy plans. Technical and administrative inquiries are managed by Dr. William Mounfield and can be directed to [email hidden]. A draft program solicitation is expected to be released on sam.gov prior to the Industry Day event.

Defense Advanced Research Projects Agcy

POSTED

DEADLINE

High-Containment Laboratory & Scientific Research ServicesThis subcontract opportunity, titled High-Containment Laboratory and Scientific Research Services, supports the National Institutes of Health Olao under the Department of Health and Human Services. The project focuses on the NIH STEAM program, requiring the provision of specialized scientific personnel to perform basic, translational, and clinical research, as well as laboratory services and scientific computing. Work is primarily based in Bethesda and involves critical operations within BSL-1 through BSL-4 and ABSL-1 through ABSL-4 containment environments. Qualified providers must demonstrate a proven capability to operate within these high-containment facilities and deliver expert research execution and animal-care roles. This opportunity is designated as a partial Small Business Set Aside under NAICS code 541714. The solicitation was posted on November 10, 2026, with a response deadline of November 17, 2026.

National Institutes Of Health Olao

POSTED

DEADLINE

Drug Development Infrastructure Supporting the Research Community in Medication Repurposing for Substance Use DisordersThe National Institutes of Health, through the National Institute on Drug Abuse, is forecasting a grant opportunity to establish a drug-development infrastructure aimed at accelerating the repurposing and repositioning of medications for substance use disorders. This initiative will provide academic and biotech investigators with essential scientific expertise and shared resources, spanning the entire development continuum from in silico discovery and preclinical validation to regulatory guidance and market-access planning. The infrastructure is designed to support user-led projects through a structured selection process and community outreach to move promising therapeutics toward clinical application. The program has a total estimated funding amount of 2,500,000 dollars with one expected award. The project is estimated to begin on April 1, 2028, and does not require cost sharing. Interested parties can coordinate with the NIDA OTIPI Program Staff regarding this effort to advance treatment options for various substance use disorder indications.

National Institutes Of Health

POSTED

DEADLINE

Pre-solicitation Notice: On-Ramp for the Department of Defense OMNIBUS IV Multiple-Award Contract

Solicitation # HT942627RE002

The Defense Health Agency Contracting Activity intends to issue a Request for Proposal in early November 2026 for an on-ramp to the OMNIBUS IV Multiple Award, Indefinite Delivery, Indefinite Quantity contract vehicle. This opportunity is specifically set aside for small businesses certified under the Small Business Administration 8(a) Program and will focus on providing military medical research and development services. Multiple new awards are expected, all of which will align with the existing unrestricted contract vehicle. The OMNIBUS IV vehicle operates with a cumulative ceiling of 10 billion dollars and a performance period extending through June 19, 2032, including option years. To date, the contract has seen over 690 million dollars awarded across 61 task orders to various end users, including the Naval Supply Systems Command and the Uniformed Services University of the Health Sciences. Task orders may be competed via fair opportunity or through specific exceptions such as small business set-asides.

Defense Health Agency

POSTED

DEADLINE

USDA SBIR/STTR Topic 8.2 — Plant Production and Protection - Biology

Solicitation # USDA-NIFA-TOPIC-8.2

The USDA National Institute of Food and Agriculture is soliciting proposals under Topic 8.2 for Plant Production and Protection - Biology. This initiative focuses on advancing crop production and protection through the development of innovative plant breeding methods, diagnostic technologies for diseases, and the creation of new food and non-food crop plants. Research efforts are directed toward improving plant characteristics to mitigate biotic and abiotic stresses, developing new genotypes for commercial applications, and creating tools to support the health of natural and domesticated pollinators. This opportunity is a total small business set-aside under the SBIR/STTR mandate, restricting eligibility to companies with fewer than 500 employees. Managed by the United States Department of Agriculture, the program is led by Dr. Christopher Philips. Interested parties can find further details and application guidelines through the NIFA website.

National Institute of Food and Agriculture

POSTED

DEADLINE

BWA Identification Core & Assay DevelopmentThe BWA Identification Core and Assay Development subcontract, managed under the Department of Defense agency W6QK Acc-Apg, focuses on the creation and supply of core biological detection technology and assays for U.S. Navy EMBD IDS projects. The primary objective is to develop assays capable of identifying toxins, viruses, and bacteria with sensitivity and specificity levels that match laboratory PCR standards. To ensure accuracy, the project utilizes biological agent panels and simulants during the testing phase. The scope of work requires the delivery of a biological detection engine, specialized assay kits, and comprehensive performance data. This effort is categorized under NAICS code 541714 and is slated for performance in Gunpowder. The solicitation was posted on November 6, 2026, with a response deadline set for December 7, 2026.

POSTED

DEADLINE

Solicitation # DARPA-PS-26-137

The Firefox program, managed by the DARPA Biological Technologies Office, is a 36-month, three-phase initiative seeking to develop a 100-channel, non-invasive brain-computer interface with 50-micron spatial and 100-microsecond temporal resolution. The program focuses on two primary technical hurdles: the creation of components for dynamic rastering and scanning of coherent optical signals to target multiple regions of interest, and the development of non-digital data processing architectures capable of handling high data rates and computational burdens. Multiple awards are anticipated, with funding ranging between 4 million and 7 million dollars per award. Awards will be issued as Other Transaction for Prototype agreements under 10 U.S.C. 4022, utilizing a milestone-based payment schedule. The selection process is multi-staged, beginning with an abstract evaluation based on technical comprehension, technical ability, and budget realism, followed by an Oral Presentation Proposal for selected candidates. Proposers must be registered in the System for Award Management and possess a Unique Entity Identifier. Key compliance requirements include adherence to ANSI laser safety limits for human tissue exposure, Cybersecurity Maturity Model Certification, and strict guidelines regarding organizational conflicts of interest and foreign influence risk assessments.

Defense Advanced Research Projects Agcy

POSTED

DEADLINE

Future Program: Laguna

Solicitation # DARPA-SN-27-15

Special Notice DARPA-SN-27-15, issued by the Defense Advanced Research Projects Agency Biological Technologies Office, serves as a public notification for the forthcoming Laguna program. This notice is intended for information and program planning purposes and does not constitute a formal solicitation for proposals. The program is anticipated to be a 36-month effort focused on the development and demonstration of defense-relevant specialty products formulated from U.S.-produced raw materials. These products must meet or exceed the critical performance requirements of existing military materials. Key deliverables for the program include predictive tools for material properties, life cycle assessments, technoeconomic analyses, and commercialization strategy plans. The primary point of contact for the initiative is Dr. William Mounfield. While this notice provides an overview of research interests, DARPA will not accept submissions at this time. Formal solicitation details and submission instructions will be posted on sam.gov upon release. All communications regarding this notice must remain unclassified.

Defense Advanced Research Projects Agcy

POSTED

DEADLINE

Leveraging NAMs to understand disease triggers, discover early biomarkers and develop new classes of therapeutic strategies for Type 1 Diabetes (U01 Clinical Trial Not Allowed)The National Institutes of Health is seeking research projects to investigate the initiation and early progression of Type 1 Diabetes using human-relevant New Approach Methodologies. Utilizing human cells, tissues, organoids, and microphysiological systems, the initiative aims to identify early biomarkers and therapeutic targets to prevent significant pancreatic beta cell loss. This effort focuses on combining innovative experimental and computational approaches to uncover the cellular and molecular mechanisms driving the disease. Selected awardees will join the Human Islet Research Network to foster collaboration, share data and tools, and coordinate the use of limited human pancreatic tissues. With total program funding of 12 million dollars and an expected 12 awards, the project is scheduled to begin around November 1, 2027. The overarching goal is to accelerate the translation of research discoveries into practical preventive and treatment strategies through a harmonized, multi-laboratory effort.

National Institutes Of Health

POSTED

9 days ago

DEADLINE

N/A

AI Contract Overview

The National Institutes of Health intends to award a firm-fixed-price purchase order to Ingenious Targeting Laboratory Inc. for the creation of a custom inducible knockin mouse. This specific requirement involves an endogenous Gcm2 genomic modification, which distinguishes it from generic CRISPR/Cas9 mouse generation or services using heterologous promoters in a transgene. Based on market research, Ingenious Targeting Laboratory Inc. has been identified as the only responsible source capable of meeting these precise technical specifications. While this notice is not a request for competitive quotes, the government allows small businesses to submit written capability statements to demonstrate their ability to perform the requirement. Responses must be submitted to the primary point of contact by 9:00 a.m. EDT on September 1, 2026. If no other capable vendors are identified, the award is expected to be issued approximately five days after the notice date.

General Info

NIH awards Ingenious Targeting Laboratory Inc. for custom Gcm2 inducible knockin mouse creation.

Agency

Department Of Health And Human Services → National Institutes Of Health Olao

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Place of Performance

Bethesda, MD, 20892, USA

Set-Aside

NONE

Documents

No documents available

No documents were posted with this contract.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PhaseClosed

PostedAug 27

Presolicitation

Response DeadlineSep 1

Deadline has passed

Submission Closed

09/01/2026, 09:00:00 AM EDT

Find active opportunities like this

Get full access to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyDepartment Of Health And Human Services → National Institutes Of Health Olao

Contacts1 person available

OfficeBETHESDA, MD, 20892, USA

Organization / AgencyDepartment Of Health And Human Services → National Institutes Of Health Olao

Office AddressBETHESDA, MD, 20892, USA

Contacts

MAI VENSON

Full Description

Notice of Intent: CUSTOM INDUCIBLE KNOCKIN MOUSE

(PCA-NIDDK-02527)

The National Institutes of Health intends to award a Firm-Fixed-Price Purchase Order to Ingenious Targeting Laboratory Inc.

In accordance with FAR Part 6.302-1, Ingenious Targeting Laboratory Inc is the only responsible source presently identified as capable of satisfying the complete technical requirements of this Custom Inducible Knockin Mouse.

The Government determined that CRISPR/Cas9 and custom mouse-model generation services are available from multiple sources. However, the Government's requirement is for a specific endogenous Gcm2 genomic modification, rather than generic CRISPR/Cas9 mouse generation.

Alternative services offering Gcm2 expression through a heterologous promoter in a transgene do not satisfy this requirement because they do not modify the endogenous Gcm2 gene.

Based on the market research conducted to date, Ingenious Targeting Laboratory Inc. is the only responsible source identified as capable of satisfying the Government's complete technical requirement.

This notice is not a request for competitive quotes. Ingenious Targeting Laboratory Inc. is the provider of CRISPR/Cas9 precision genomic-editing services specifically suited to the generation of the required Gcm2 knock-in mouse line this service. However, any available small businesses (e.g., 8(a), service-disabled veteran owned small business, HUBZone small business, small disadvantaged business, veteran-owned small business, and women-owned small business) as stated herein may submit a written capability statement that clearly supports and demonstrates their ability to perform the requirement. A determination by the Government to compete this proposed award based upon responses to this notice is solely within the discretion of the Government.

It is anticipated that an award will be issued approximately five (5) days after the date of this notice unless the Government determines that another vendor has the capability to meet this requirement.

Please email responses to Sign up to see this detail no later than 09:00 a.m. EDT on September 01, 2026.